针对阿尔德海德修饰的阿波利波蛋白B-100序列的重组人体抗体抑制动脉样硬化
Alexandru Schiopu1, Jenny Bengtsson, Ingrid Söderberg
1Department of Medicine, Malmö University Hospital, Lund University, Malmö, Sweden. Alexandru.Schiopu@medforsk.mas.lu.se.
Circulation
|September 29, 2004
概括
针对氧化LDL的抗体,特别是malondialdehyde修饰的Apolipoprotein B-100,减少了小鼠的动脉样硬化. 这表明被动免疫可能为心血管疾病提供新的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- 动脉样硬化是一种动脉样硬化.
背景情况:
- 低密度脂蛋白 (LDL) 的积累和氧化是动脉样硬化发展的关键.
- 对氧化LDL的免疫反应,特别是对阿尔德海德修饰的阿波利波蛋白B-100 (apoB-100) 的免疫反应,可能具有保护作用.
- 氧化LDL被免疫系统识别出来.
研究的目的:
- 研究抗氧化LDL抗体的治疗潜力.
- 探索免疫反应在动脉样硬化中的作用.
- 开发心血管疾病的新型治疗方法.
主要方法:
- 制造的人类IgG1抗体对抗马隆迪甲 (MDA) 修饰的apoB-100.
- 对apoE-/-小鼠进行了抗体治疗,并评估了动脉样硬化.
- 在体外对单细胞结合和氧化LDL吸收的评估抗体效应.
主要成果:
- 一个抗体显著降低了动脉样硬化程度和氧化LDL和巨细胞的斑块含量,以剂量依赖的方式.
- 抗体增加了单细胞结合和细胞培养中的氧化LDL的吸收.
- 对照抗体没有显示这些效应.
结论:
- 针对MDA修饰的apoB-100的抗体调解了体外保护性免疫反应.
- 对这些表位体的被动免疫是心血管疾病的潜在治疗策略.
- 对动脉样硬化的抗体疗法进行进一步的研究是有必要的.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


